Literature DB >> 8098632

Trimetazidine for prevention of hepatic injury induced by ischaemia and reperfusion in rats.

E C Tsimoyiannis1, K J Moutesidou, C M Moschos, M Karayianni, S Karkabounas, O B Kotoulas.   

Abstract

OBJECTIVE: To assess the effect of trimetazidine (an anti-anginal drug that acts as a scavenger of oxygen free radicals) in the protection of hepatocytes after a 90 minute period of warm ischaemia followed by reperfusion in rats.
DESIGN: Prospective study. MATERIAL: 80 Wistar rats.
INTERVENTIONS: 20 Rats were given a single dose of trimetazidine 2.5 mg/kg intravenously 30 minutes before the induction of ischaemia; 20 received the same dose intraperitoneally twice a day for five days before the experiment and one dose intravenously 30 minutes before; 20 were given a single dose of 2.5 mg/kg intravenously after reperfusion had been started; and 20 acted as controls. All rats underwent liver biopsy through a laparotomy incision on postoperative days 2, 7, and 21, and the activities of liver enzymes in their blood were measured before induction of ischaemia and two, seven, 14, and 21 days afterwards. OUTCOME MEASURES: Histological changes and serum enzyme activities.
RESULTS: The amount of centrilobular necrosis of hepatocytes, and the activity of hepatic enzymes were greatest on day 2, as was the reduction in superoxide dismutase activity in the erythrocytes. A single dose of trimetazidine, whether given before or after the ischaemic episode, gave significant protection to hepatocytes, but pretreatment for five days was even more effective.
CONCLUSION: Trimetazidine protected rats' livers from injury after a period of warm ischaemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098632

Source DB:  PubMed          Journal:  Eur J Surg        ISSN: 1102-4151


  7 in total

1.  Effects of sulfasalazine on lipid peroxidation and histologic liver damage in a rat model of obstructive jaundice and obstructive jaundice with lipopolysaccharide-induced sepsis.

Authors:  Musa Dirlik; Aydin Karahan; Hakan Canbaz; Mehmet Caglikulekci; Ayşe Polat; Lulufer Tamer; Suha Aydin
Journal:  Curr Ther Res Clin Exp       Date:  2009-08

2.  Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.

Authors:  Alper O Onbasili; Yavuz Yeniceriglu; Pinar Agaoglu; Aslihan Karul; Tarkan Tekten; Harun Akar; Guzel Discigil
Journal:  Heart       Date:  2006-10-25       Impact factor: 5.994

Review 3.  Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention.

Authors:  Diana L Diesen; Paul C Kuo
Journal:  J Surg Res       Date:  2009-10-27       Impact factor: 2.192

4.  Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy.

Authors:  Refik Kayali; Jin-Mo Ku; Gregory Khitrov; Michael E Jung; Olga Prikhodko; Carmen Bertoni
Journal:  Hum Mol Genet       Date:  2012-06-12       Impact factor: 6.150

5.  Trimetazidine: is it a promising drug for use in steatotic grafts?

Authors:  Ismail Ben Mosbah; Araní Casillas-Ramírez; Carme Xaus; Anna Serafín; Joan Roselló-Catafau; Carmen Peralta
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

6.  Cardioprotective Effects of Oral Trimetazidine in Diabetic Patients With Anterior Wall Myocardial Infarction Treated with Thrombolysis.

Authors:  Mohamed Shehata
Journal:  Cardiol Res       Date:  2014-05-15

7.  Trimetazidine for prevention of induced ischemia and reperfusion of guinea pig retina.

Authors:  T Demir; B Turgut; I Ozercan; F C Gul; N Ilhan; U Celiker
Journal:  Clin Ophthalmol       Date:  2010-02-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.